Business Wire

Lattice Advances Low Power FPGA Leadership with New Small and Mid-range FPGA Offerings

10.12.2024 19:00:00 CET | Business Wire | Press release

Share

‒ Introduces Lattice Nexus 2 next-gen small FPGA platform, extends mid-range portfolio with Lattice Avant 30 and Avant 50 devices, and enhances capabilities of application-specific solution stacks and design software tools ‒

Today, at Lattice Developers Conference 2024, Lattice Semiconductor (NASDAQ: LSCC) expanded its edge to cloud FPGA innovation leadership with the launch of exciting new hardware and software solutions. The new Lattice Nexus™ 2 next-gen small FPGA platform and the first device family based on the platform, Lattice Certus™-N2 general purpose FPGAs, offer advanced connectivity, optimized power and performance, and class-leading security. Lattice also announced new mid-range FPGA device capacity options – Lattice Avant™ 30 and Avant™ 50 – and new versions of Lattice design software tools and application-specific solution stacks to help accelerate customer time-to-market.

“At Lattice, we are proud to lead technological advancements in low power, small form factor FPGAs, ensuring our customers have the optimal devices, tools, and solutions to design groundbreaking applications that are power efficient, fast, and secure,” said Esam Elashmawi, Chief Strategy and Marketing Officer, Lattice Semiconductor. “From the edge to the cloud across a variety of industries, FPGAs stand at the forefront of innovation, and we’re committed to delivering versatile and robust small and mid-range FPGA solutions that enable our customers and partners to unlock their full potential.”

Advancing Small FPGA Innovation

The new Lattice Nexus 2 small FPGA platform combines connectivity advancements, power and performance optimizations, and leading security and reliability capabilities to meet the growing demand for edge applications requiring efficient processing, bridging, and control capabilities.

Built on the proven 16 nm FinFET TSMC process technology, Lattice Nexus 2 continues company’s low power, small FPGA leadership equipping customers with

  • Power Efficiency
    • Up to 3X lower power than similar class competitive devices, enabling power and thermal design efficiencies, improved operating costs, and enhanced reliability.
    • Up to 10X energy efficient edge sensor monitoring than similar class competitive devices.
  • Performance
    • Up to 3.2X faster MIPI speed than similar class competitive devices for faster connectivity and data transfer.
    • Up to 10X faster configuration time than similar class competitive devices enhancing overall efficiency, fault tolerance, and security in safety-critical applications.
  • Form Factor
    • Up to 5X smaller size than similar class competitive devices, enabling simplified, efficient system designs.
  • Connectivity
    • Combines multi-protocol 16G SERDES with PCIe® Gen 4 controller, high performance I/O, high speed LPDDR4 memory interface support, and industry-leading MIPI D & C-PHY up to 7.98 Gbps.
  • Security
    • Industry-leading security with 256-bit AES-GCM and SHA3-512; compliant with FIPS 140-3 level 2 standards.
    • Crypto agility, post-quantum ready, and anti-temper protection.
    • Integrated flash enabling faster and more secure configuration.
    • End user options for customers’ data-in-motion security needs.

The Lattice Nexus 2 platform is architected for scalability that will enable the rapid development of multiple new device families, starting today with the launch of the Lattice Certus™-N2 general purpose FPGA family. Lattice Certus-N2 FPGAs are sampling today and are supported by the latest releases of Lattice Propel™ and Lattice Radiant™ design software.

Extending Mid-Range FPGA Portfolio

Built on the award-winning Lattice Avant platform, the Avant 30 and Avant 50 offers new capacity options for customers to enable edge optimized and advanced connectivity applications development. These devices provide customers more options for connectivity, functional capacity, and features.

Expanded Solution Stacks

Lattice announced new versions of Lattice Radiant™ and Lattice Propel™ software tools that support the new Lattice Nexus 2 FPGA platform, Lattice Certus-N2 FPGA family, and Lattice Avant devices, alongside new features including RISC-V® variants and improved debug, power calculation, and ease-of-use.

Lattice also announced four solution stack updates in edge AI with Lattice sensAI™, embedded vision with Lattice mVision™, factory automation with Lattice Automate™, and automotive designs with Lattice Drive™. These updates include improved performance with enhanced application-specific features and expanded IP, demo, and reference designs.

These announcements were made today during the livecast at Lattice Developers Conference 2024, a replay of which will soon be available on the event portal site. Lattice Developers Conference is taking place virtually Dec. 10-11, 2024, featuring an incredible lineup of keynotes, breakout sessions, and a robust showcase of FPGA-based technology demonstrations from Lattice and other industry leaders.

For more information on the new products, please read the latest blog and visit:

About Lattice Semiconductor

Lattice Semiconductor (NASDAQ: LSCC) is the low power programmable leader. We solve customer problems across the network, from the Edge to the Cloud, in the growing Communications, Computing, Industrial, Automotive, and Consumer markets. Our technology, long-standing relationships, and commitment to world-class support let our customers quickly and easily unleash their innovation to create a smart, secure, and connected world.

For more information about Lattice, please visit www.latticesemi.com. You can also follow us via LinkedIn, X, Facebook, YouTube, WeChat, or Weibo.

Lattice Semiconductor Corporation, Lattice Semiconductor (& design), and specific product designations are either registered trademarks or trademarks of Lattice Semiconductor Corporation or its subsidiaries in the United States and/or other countries. The use of the word “partner” does not imply a legal partnership between Lattice and any other entity.

GENERAL NOTICE: Other product names used in this publication are for identification purposes only and may be trademarks of their respective holders.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241210483055/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye